Addex Therapeutics (ADXN) Amortization of Deferred Charges (2022 - 2026)
Addex Therapeutics (ADXN) posted Amortization of Deferred Charges of $5.9 billion for Q1 2026, down 67.21% sequentially from $17.9 billion in Q1 2025, and down 67.21% YoY from $17.9 billion in Q1 2025.
Addex Therapeutics (ADXN) Amortization of Deferred Charges (2022 - 2026) Analysis & Trends
Addex Therapeutics has reported Amortization of Deferred Charges for 5 years, with the latest figure at $5.9 billion in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Addex Therapeutics | 534.71 Mn | 534.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.87 Bn |
| Mar 31, 2026 | 5.87 Bn |
| Mar 31, 2025 | 17.89 Bn |
| Mar 31, 2025 | 17.89 Bn |
| Sep 30, 2024 | 122.63 Bn |
| Sep 30, 2024 | 122.63 Bn |
| Jun 30, 2024 | -111.22 Bn |
| Jun 30, 2024 | -111.22 Bn |
| Mar 31, 2024 | -112,451.01 |
| Mar 31, 2024 | -112,451.01 |
| Sep 30, 2023 | -156.18 Bn |
| Sep 30, 2023 | -156.18 Bn |
| Jun 30, 2023 | 166.14 Bn |
| Jun 30, 2023 | 166.14 Bn |
| Mar 31, 2023 | 11,704.67 |
| Mar 31, 2023 | 11,704.67 |
| Sep 30, 2022 | -112,177.23 |
| Sep 30, 2022 | -112,177.23 |
| Jun 30, 2022 | 89,973.28 |
| Jun 30, 2022 | 89,973.28 |